Peter James Anderson

US Patent:

8067022, Nov 29, 2011

Filed:

Jul 20, 2001

Appl. No.:

09/910388

Inventors:

Lawrence L. Kunz - Sammamish WA, US
Peter G. Anderson - Birmingham AL, US

Assignee:

Boston Scientific SciMed, Inc. - Maple Grove MN

International Classification:

A61F 2/00
A61K 31/00

US Classification:

424423, 514 1

Abstract:

Methods are provided for inhibiting stenosis following vascular trauma or disease in a mammalian host, comprising administering to the host a therapeutically effective dosage of a therapeutic conjugate containing a vascular smooth muscle binding protein that associates in a specific manner with a cell surface of the vascular smooth muscle cell, coupled to a therapeutic agent dosage form that inhibits a cellular activity of the muscle cell. Methods are also provided for the direct and/or targeted delivery of therapeutic agents to vascular smooth muscle cells that cause a dilation and fixation of the vascular lumen by inhibiting smooth muscle cell contraction, thereby constituting a biological stent. Also discussed are mechanisms for in vivo vascular smooth muscle cell proliferation modulation, agents that impact those mechanisms and protocols for the use of those agents.

US Patent:

8097642, Jan 17, 2012

Filed:

Feb 27, 2007

Appl. No.:

11/679650

Inventors:

Lawrence L. Kunz - Sammamish WA, US
Peter G. Anderson - Birmingham AL, US

International Classification:

A61K 31/40
A61K 31/35

US Classification:

514411, 514455

Abstract:

Methods are provided for inhibiting stenosis following vascular trauma or disease in a mammalian host, comprising administering to the host a therapeutically effective dosage of a therapeutic conjugate containing a vascular smooth muscle binding protein that associates in a specific manner with a cell surface of the vascular smooth muscle cell, coupled to a therapeutic agent dosage form that inhibits a cellular activity of the muscle cell. Methods are also provided for the direct and/or targeted delivery of therapeutic agents to vascular smooth muscle cells that cause a dilation and fixation of the vascular lumen by inhibiting smooth muscle cell contraction, thereby constituting a biological stent.

US Patent:

8158670, Apr 17, 2012

Filed:

Jan 4, 2007

Appl. No.:

11/650059

Inventors:

Lawrence L. Kunz - Sammamish WA, US
Peter G. Anderson - Birmingham AL, US

Assignee:

Boston Scientific Scimed, Inc. - Maple Grove MN

International Classification:

A61K 31/40
A61K 31/35

US Classification:

514411, 514455

Abstract:

Methods are provided for inhibiting stenosis following vascular trauma or disease in a mammalian host, comprising administering to the host a therapeutically effective dosage of a therapeutic conjugate containing a vascular smooth muscle binding protein that associates in a specific manner with a cell surface of the vascular smooth muscle cell, coupled to a therapeutic agent dosage form that inhibits a cellular activity of the muscle cell. Methods are also provided for the direct and/or targeted delivery of therapeutic agents to vascular smooth muscle cells that cause a dilation and fixation of the vascular lumen by inhibiting smooth muscle cell contraction, thereby constituting a biological stent.

US Patent:

20090196931, Aug 6, 2009

Filed:

Apr 3, 2009

Appl. No.:

12/418209

Inventors:

Lawrence L. Kunz - Sammamish WA, US
Peter G. Anderson - Birmingham AL, US

International Classification:

A61K 9/14
A61K 9/00
A61K 31/553
A61K 31/407
A61K 38/18
A61K 31/135
A61K 31/337

US Classification:

424489, 424400, 51421108, 514411, 514 12, 514646, 514449

Abstract:

Methods are provided for inhibiting or treating stenosis or restenosis following vascular trauma or disease in a mammalian host, comprising administering to the host a therapeutically effective amount of a therapeutic agent via a catheter. Also provided is a catheter adapted for administering a therapeutically effective amount of a therapeutic agent to a mammalian host for inhibiting or treating stenosis or restenosis.

US Patent:

20110300221, Dec 8, 2011

Filed:

Aug 15, 2011

Appl. No.:

13/209956

Inventors:

Lawrence L. Kunz - Sammamish WA, US
Peter G. Anderson - Birmingham AL, US

International Classification:

A61K 9/14
A61P 7/00
A61P 9/08
A61K 31/337

US Classification:

424490, 514449

Abstract:

Methods are provided for inhibiting stenosis following vascular trauma or disease in a mammalian host, comprising administering to the host a therapeutically effective dosage of a therapeutic conjugate containing a vascular smooth muscle binding protein that associates in a specific manner with a cell surface of the vascular smooth muscle cell, coupled to a therapeutic agent dosage form that inhibits a cellular activity of the muscle cell. Methods are also provided for the direct and/or targeted delivery of therapeutic agents to vascular smooth muscle cells that cause a dilation and fixation of the vascular lumen by inhibiting smooth muscle cell contraction, thereby constituting a biological stent.

US Patent:

20120195951, Aug 2, 2012

Filed:

Apr 13, 2012

Appl. No.:

13/446760

Inventors:

Lawrence L. Kunz - Sammamish WA, US
Peter G. Anderson - Birmingham AL, US

International Classification:

A61F 2/82

US Classification:

424423

Abstract:

Methods are provided for inhibiting stenosis following vascular trauma or disease in a mammalian host, comprising administering to the host a therapeutically effective dosage of a therapeutic conjugate containing a vascular smooth muscle binding protein that associates in a specific manner with a cell surface of the vascular smooth muscle cell, coupled to a therapeutic agent dosage form that inhibits a cellular activity of the muscle cell. Methods are also provided for the direct and/or targeted delivery of therapeutic agents to vascular smooth muscle cells that cause a dilation and fixation of the vascular lumen by inhibiting smooth muscle cell contraction, thereby constituting a biological stent.

US Patent:

58114475, Sep 22, 1998

Filed:

May 25, 1995

Appl. No.:

8/450793

Inventors:

Lawrence L. Kunz - Redmond WA
Richard A. Klein - Lynnwood WA
John M. Reno - Brier WA
David J. Grainger - Cambridge, GB2
James C. Metcalfe - Cambridge, GB2
Peter L. Weissberg - Cambridge, GB2
Peter G. Anderson - Birmingham AL

Assignee:

NeoRx Corporation - Seattle WA

International Classification:

A61K 3140

US Classification:

514411

Abstract:

Methods are provided for inhibiting stenosis following vascular trauma or disease in a mammalian host, comprising administering to the host a therapeutically effective dosage of a therapeutic conjugate containing a vascular smooth muscle binding protein that associates in a specific manner with a cell surface of the vascular smooth muscle cell, coupled to a therapeutic agent dosage form that inhibits a cellular activity of the muscle cell. Methods are also provided for the direct and/or targeted delivery of therapeutic agents to vascular smooth muscle cells that cause a dilation and fixation of the vascular lumen by inhibiting smooth muscle cell contraction, thereby constituting a biological stent. Also discussed are mechanisms for in vivo vascular smooth muscle cell proliferation modulation, agents that impact those mechanisms and protocols for the use of those agents.

US Patent:

60746599, Jun 13, 2000

Filed:

Jul 10, 1998

Appl. No.:

9/113733

Inventors:

Lawrence L. Kunz - Redmond WA
Richard A. Klein - Lynnwood WA
John M. Reno - Brier WA
David J. Grainger - Cambridge, GB
James C. Metcalfe - Cambridge, GB
Peter L. Weissberg - Cambridge, GB
Peter G. Anderson - Birmingham AL

Assignee:

NoeRx Corporation - Seattle WA

International Classification:

A61F 200

US Classification:

424423

Abstract:

Methods are provided for inhibiting stenosis following vascular trauma or disease in a mammalian host, comprising administering to the host a therapeutically effective dosage of a therapeutic conjugate containing a vascular smooth muscle binding protein that associates in a specific manner with a cell surface of the vascular smooth muscle cell, coupled to a therapeutic agent dosage form that inhibits a cellular activity of the muscle cell. Methods are also provided for the direct and/or targeted delivery of therapeutic agents to vascular smooth muscle cells that cause a dilation and fixation of the vascular lumen by inhibiting smooth muscle cell contraction, thereby constituting a biological stent. Also discussed are mechanisms for in vivo vascular smooth muscle cell proliferation modulation, agents that impact those mechanisms and protocols for the use of those agents.